CompletedPHASE1, PHASE2NCT02213913
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
Studying Lymphomatoid granulomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Chicago
- Principal Investigator
- Sonali SmithUniversity of Chicago
- Intervention
- lenalidomide(drug)
- Enrollment
- 55 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2024
Study locations (6)
- Rush University Medical Center, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
- NorthShore University HealthSystem, Evanston, Illinois, United States
- Illinois Cancer Care, Peoria, Illinois, United States
- University of Maryland, Baltimore, Maryland, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02213913 on ClinicalTrials.gov